Alpha 2.0
Login Register
» Articles » PMID: 32595436

Enoxaparin-Induced Liver Injury

Overview
Journal Case Rep Gastroenterol
Publisher Karger
Specialty Gastroenterology
Date 2020 Jun 30
PMID 32595436
Citations 3
Authors
Shehriyar Mehershahi
Nikhitha Mantri
Aneesh Kumar
Shaikh Danial
Patel Harish
Affiliations
Soon will be listed here.
Abstract

Enoxaparin, a form of low-molecular-weight heparin, can cause a rare, underreported, and often reversible form of hepatocellular injury. This report describes a case of enoxaparin-induced hepatotoxicity in a 61-year-old male diagnosed with pulmonary embolism. Elevations of liver enzymes were noted within 1 week of starting the drug, followed by a dramatic improvement upon its discontinuation, with subsequent normalization in the following days.

Citing Articles

Safety profiles of fondaparinux in pregnant women: a systematic review and meta-analysis.

Shan D, Han J, Ji Y, Wu Y, Yi K Eur J Clin Pharmacol. 2025; .

PMID: 39836237 DOI: 10.1007/s00228-025-03804-y.

Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment.

Velasco de Cos G, Sanchez-Molina Acosta I, Iturralde Ros M, Maiztegi Azpitarte A, Moyano Martinez A Adv Lab Med. 2023; 2(4):575-582.

PMID: 37360893 PMC: 10197442. DOI: 10.1515/almed-2021-0048.

Verification of selective and individual pulmonary thromboembolism prophylaxes for cesarean delivery.

Kawaguchi R, Maehana T, Yamada Y, Ichikawa M, Akasaka J, Kimura F Obstet Gynecol Sci. 2023; 66(3):181-189.

PMID: 36945725 PMC: 10191768. DOI: 10.5468/ogs.22281.

Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis.

Teschke R, Danan G Medicines (Basel). 2020; 7(10).

PMID: 33003400 PMC: 7600114. DOI: 10.3390/medicines7100062.

References
1.
Arora N, Goldhaber S . Anticoagulants and transaminase elevation. Circulation. 2006; 113(15):e698-702. DOI: 10.1161/CIRCULATIONAHA.105.603100. View
2.
Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View
3.
Baker E, Loewenthal T, Salerno E, Baker W . Probable enoxaparin-induced hepatotoxicity. Am J Health Syst Pharm. 2009; 66(7):638-41. DOI: 10.2146/ajhp080311. View
4.
Carlson M, Gleason P, Sen S . Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy. 2001; 21(1):108-13. DOI: 10.1592/phco.21.1.108.34436. View
5.
Hahn K, Morales S, Lewis J . Enoxaparin-Induced Liver Injury: Case Report and Review of the Literature and FDA Adverse Event Reporting System (FAERS). Drug Saf Case Rep. 2016; 2(1):17. PMC: 5005670. DOI: 10.1007/s40800-015-0018-0. View